People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Other Health Care, Biotechnology, Healthtech, Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Radiology Partners Holdings, LLC | — | Other Health Care | Growth/Late | $1.5B | $9.1B | 2014 |
| Pathos AI, Inc. | — | Biotechnology | Series D+ | $365.0M | $2.4B | 2024 |
| Elements Behavioral Health, Inc. | — | Other Health Care | Series C | $165.2M | $1.4B | 2008 |
| Vori Health Inc. | — | Healthtech | Series C | $85.4M | $240.5M | 2025 |
| Ebh Holding Company, Inc. | — | Other Health Care | Series B | $70.9M | $871.1M | 2012 |
| Waymark, Inc. / DE | — | Other Technology | Series C | $67.0M | $278.9M | 2021 |
| PayZen Inc. | — | Other Technology | Series B | $43.6M | $218.1M | 2024 |
| Docent Health, Inc. | — | Other Health Care | Series B | $17.1M | $378.8M | 2016 |
| BetterDoctor, Inc. | — | Other Technology | Series A | $9.9M | $274.2M | 2014 |
| Curisium Inc. | — | Other | Seed | $3.5M | $42.8M | 2017 |
Mohamad Makhzoumi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mohamad Makhzoumi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Whitney | 3 | 5 |
| Nader Naini | 2 | 6 |
| Thomas Cooper | 2 | 6 |
| David Kosloff | 2 | 2 |
| David Sack | 2 | 2 |
| Rob Mahan | 2 | 2 |
| Ryan Drant | 1 | 24 |
| Jean-Francois Clavier | 1 | 10 |
| LEE SHAPIRO | 1 | 10 |
| Eric Lefkofsky | 1 | 8 |
| Vineeta Agarwala | 1 | 8 |
| Tyrell Rivers | 1 | 6 |
| Ambar Bhattacharyya | 1 | 6 |
| Jeffrey Immelt | 1 | 5 |
| Trevor Price | 1 | 4 |
| Amit Mehta | 1 | 4 |
| PETER KIM | 1 | 4 |
| Christopher Scoggins | 1 | 3 |
| Kevin Roberts | 1 | 3 |
| Greg Scott | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.